Bausch Health Companies (BHC) Intangibles (2009 - 2026)
Bausch Health Companies (BHC) reported Intangibles of $4.4 billion for Q1 2026, down 16.86% on a YoY basis from $5.3 billion in Q1 2025, and down 5.15% sequentially from $4.6 billion in Q4 2025.
Bausch Health Companies (BHC) Intangibles (2009 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 18 years of Intangibles data on file, last reported at $4.4 billion in Q1 2026.
- For the quarter ending Q1 2026, Intangibles fell 16.86% year-over-year to $4.4 billion; the trailing twelve-month figure through Mar 2026 stood at $4.4 billion (down 16.86% YoY), and the FY2025 full-year result was $4.6 billion, down 16.36% from the prior year.
- Intangibles retreated to $4.4 billion in Q1 2026, from $4.6 billion in the prior quarter.
- In the past five years, Intangibles ranged from a high of $6.7 billion in Q3 2023 to a low of $4.4 billion in Q1 2026.
- A 5-year average of $5.7 billion and a median of $5.7 billion in 2024 frame the typical range for Intangibles.
- Across the five-year window, Intangibles retreated 17.08% in 2022 and advanced 11.69% in 2023, its largest moves.
- Tracing BHC's Intangibles over 5 years: stood at $5.8 billion in 2022, then grew by 11.31% to $6.5 billion in 2023, then declined by 14.02% to $5.6 billion in 2024, then retreated by 16.36% to $4.6 billion in 2025, then decreased by 5.15% to $4.4 billion in 2026.
- Business Quant data shows BHC's Intangibles at $4.4 billion in Q1 2026, $4.6 billion in Q4 2025, and $4.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 34.07 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.61 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 959.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 21.80 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 473.93 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.48 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.23 Bn |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn | 4.40 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.40 Bn |
| Dec 31, 2025 | 4.64 Bn |
| Sep 30, 2025 | 4.83 Bn |
| Jun 30, 2025 | 5.05 Bn |
| Mar 31, 2025 | 5.30 Bn |
| Dec 31, 2024 | 5.55 Bn |
| Sep 30, 2024 | 5.65 Bn |
| Jun 30, 2024 | 5.90 Bn |
| Mar 31, 2024 | 6.18 Bn |
| Dec 31, 2023 | 6.46 Bn |
| Sep 30, 2023 | 6.73 Bn |
| Jun 30, 2023 | 5.30 Bn |
| Mar 31, 2023 | 5.55 Bn |
| Dec 31, 2022 | 5.80 Bn |
| Sep 30, 2022 | 6.02 Bn |
| Jun 30, 2022 | 6.32 Bn |
| Mar 31, 2022 | 6.63 Bn |
| Dec 31, 2021 | 6.95 Bn |
| Sep 30, 2021 | 7.26 Bn |
| Jun 30, 2021 | 7.62 Bn |